ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för cinaciguat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

17 träffar

Bibliografisk träff 2018-04-11

Synergistic stabilisation of NOsGC by cinaciguat and non-hydrolysable nucleotides: Evidence for sGC activator-induced communication between the heme-binding and catalytic domains.

Sömmer A, Behrends S.

Biochim Biophys Acta Proteins Proteom · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbapap.2018.03.010

Bibliografisk träff 2017-11-14

Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat.

Kollau A, Opelt M, Wölkart G, Gorren ACF, Russwurm M, Koesling D, Mayer B, Schrammel A.

Mol Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1124/mol.117.109918

Bibliografisk träff 2017-09-11

Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats.

Czirok S, Fang L, Radovits T, Szabó G, Szénási G, Rosivall L, Merkely B, Kökény G.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-017-10125-3

Bibliografisk träff 2016-11-17

Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.

Németh BT, Mátyás C, Oláh A, Lux Á, Hidi L, Ruppert M, Kellermayer D, Kökény G, Szabó G, Merkely B, Radovits T.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep37166

Bibliografisk träff 2016-04-27

Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice.

de Oliveira MG, Calmasini FB, Alexandre EC, De Nucci G, Mónica FZ, Antunes E.

Am J Physiol Renal Physiol · research support, non-u.s. gov't; journal article · DOI 10.1152/ajprenal.00041.2016

Bibliografisk träff 2015-10-31

The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.

Mátyás C, Németh BT, Oláh A, Hidi L, Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icöz S, Kökény G, Horváth EM, Szabó G, Merkely B, Radovits T.

Cardiovasc Diabetol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12933-015-0309-x

Bibliografisk träff 2014-09-08

Influence of cinaciguat on gastrointestinal motility in apo-sGC mice.

Cosyns SM, Huyghe L, Thoonen R, Stasch JP, Brouckaert P, Lefebvre RA.

Neurogastroenterol Motil · research support, non-u.s. gov't; journal article · DOI 10.1111/nmo.12424

Bibliografisk träff 2013-10-24

Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics.

Rekowski MVW, Kumar V, Zhou Z, Moschner J, Marazioti A, Bantzi M, Spyroulias GA, van den Akker F, Giannis A, Papapetropoulos A.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm400539d

Bibliografisk träff 2012-11-07

The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.

Irvine JC, Ganthavee V, Love JE, Alexander AE, Horowitz JD, Stasch JP, Kemp-Harper BK, Ritchie RH.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0044481

Bibliografisk träff 2012-06-19

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.

Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A, COMPOSE Investigators and Coordinators.

Eur J Heart Fail · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/eurjhf/hfs093

Bibliografisk träff 2012-03-30

Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.

Surmeli NB, Marletta MA.

Chembiochem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/cbic.201100809

Bibliografisk träff 2011-08-25

Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.

Lettieri JT, Scheerans C, Blunck M, Mazzu AL, Frey R, Mück W, Sundaresan PR.

J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1177/0091270011410567

Bibliografisk träff 2011-08-19

Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.

Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, Wright J, Stasch JP, Abman SH.

Am J Physiol Lung Cell Mol Physiol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1152/ajplung.00138.2010

Bibliografisk träff 2010-09-01

Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.

Tamargo J, Duarte J, Caballero R, Delpón E.

Curr Opin Investig Drugs · research support, non-u.s. gov't; journal article

Bibliografisk träff 2010-05-12

Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.

Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, Beuve A, van den Akker F.

J Biol Chem · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m110.111559

Bibliografisk träff 2010-01-01

Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.

Mueck W, Frey R.

Clin Pharmacokinet · journal article · DOI 10.2165/11317590-000000000-00000

Bibliografisk träff 2008-09-08

Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.

Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1177/0091270008322906